Portland, OR -- (SBWire) -- 07/31/2017 --Intrauterine contraceptive device (IUCD) is a reversible, long acting T-shaped device, which is inserted into uterus for contraception purposes. It prevents fertilization of eggs in the uterus and thus, helps to avoid pregnancy. IUCDs can provide contraception for 3 to12 years after insertion into the vagina, depending on type of ICUD and preference. IUCDs do not interfere in sexual intercourse or breastfeeding and can be used as an effective alternative to contraceptive pills. It can be inserted immediately after delivery or abortion. Women are able to retain fertility rapidly after its removal. IUCDs are widely used due to lower failure rates and cost effective nature for long-term use.
Get full summary of the Report : https://www.alliedmarketresearch.com/north-american-intrauterine-contraceptive-devices-market
The report provides, comprehensive competitive analysis and profiles of major market players such as Bayer Healthcare AG, Teva Pharmaceutical Industries Ltd., Actavis PLC, Medicines360, Trimedic Supply Network Ltd., Medisafe Distribution Inc., and Pace Pharmaceuticals Inc. have been provided in this report. The leading market players have adopted mergers & acquisitions and partnerships as one of the key developmental strategy., in order to gain strong foothold of market.
Request Sample Report : https://www.alliedmarketresearch.com/request-toc-and-sample/798
KEY MARKET SEGMENTS
BY TYPE
-Hormonal IUCD
-Copper IUCD
BY GEOGRAPHY
-United States
-Canada
-Mexico
North American Intrauterine Contraceptive Devices (IUCD) Market - Opportunities and Forecast, 2014 - 2022